Shenzhen Hepalink Pharmaceutical Group Full Year 2024 Earnings: EPS: CN¥0.44 (vs CN¥0.53 loss in FY 2023)

Shenzhen Hepalink Pharmaceutical Group (SZSE:002399) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥5.28b (down 3.0% from FY 2023).
• Net income: CN¥646.7m (up from CN¥783.3m loss in FY 2023).
• Profit margin: 12% (up from net loss in FY 2023). The move to profitability was driven by lower expenses.
• EPS: CN¥0.44 (up from CN¥0.53 loss in FY 2023).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shenzhen Hepalink Pharmaceutical Group Earnings Insights

Looking ahead, revenue is forecast to grow 6.3% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Pharmaceuticals industry in China.

Performance of the Chinese Pharmaceuticals industry.

The company's shares are up 5.0% from a week ago.

Balance Sheet Analysis

While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Shenzhen Hepalink Pharmaceutical Group's balance sheet.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.